Summary
Background
Dietary advice and medical treatments are recommended to patients with irritable bowel syndrome (IBS). Studies have not yet compared the efficacy of dietary treatment with pharmacological treatment targeting the predominant IBS symptom. We therefore aimed to compare the effects of two restrictive dietary treatment options versus optimised medical treatment in people with IBS.
Methods
This single-centre, single-blind, randomised controlled trial was conducted in a specialised outpatient clinic at the Sahlgrenska University Hospital, Gothenburg, Sweden. Participants (aged ≥18 years) with moderate-to-severe IBS (Rome IV; IBS Severity Scoring System [IBS-SSS] ≥175) and no other serious diseases or food allergies were randomly assigned (1:1:1) by web-based randomisation to receive a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) plus traditional IBS dietary advice recommended by the UK National Institute for Health and Care Excellence (hereafter the LFTD diet), a fibre-optimised diet low in total carbohydrates and high in protein and fat (hereafter the low-carbohydrate diet), or optimised medical treatment based on predominant IBS symptom. Participants were masked to the names of the diets, but the pharmacological treatment was open-label. The intervention lasted 4 weeks, after which time participants in the dietary interventions were unmasked to their diets and encouraged to continue during 6 months’ follow-up, participants in the LFTD group were instructed on how to reintroduce FODMAPs, and participants receiving pharmacological treatment were offered diet counselling and to continue with their medication. The primary endpoint was the proportion of participants who responded to the 4-week intervention, defined as a reduction of 50 or more in IBS-SSS relative to baseline, and was analysed per modified intention-to-treat (ie, all participants who started the intervention). Safety was analysed in the modified intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02970591, and is complete.
Findings
Between Jan 24, 2017, and Sept 2, 2021, 1104 participants were assessed for eligibility and 304 were randomly assigned. Ten participants did not receive their intervention after randomisation and thus 294 participants were included in the modified intention-to-treat population (96 assigned to the LFTD diet, 97 to the low-carbohydrate diet, and 101 to optimised medical treatment). 241 (82%) of 294 participants were women and 53 (18%) were men and the mean age was 38 (SD 13). After 4 weeks, 73 (76%) of 96 participants in the LFTD diet group, 69 (71%) of 97 participants in the low-carbohydrate diet group, and 59 (58%) of 101 participants in the optimised medical treatment group had a reduction of 50 or more in IBS-SSS compared with baseline, with a significant difference between the groups (p=0·023). 91 (95%) of 96 participants completed 4 weeks in the LFTD group, 92 (95%) of 97 completed 4 weeks in the low-carbohydrate group, and 91 (90%) of 101 completed 4 weeks in the optimised medical treatment group. Two individuals in each of the intervention groups stated that adverse events were the reason for discontinuing the 4-week intervention. Five (5%) of 91 participants in the optimised medical treatment group stopped treatment prematurely due to side-effects. No serious adverse events or treatment-related deaths occurred.
Interpretation
Two 4-week dietary interventions and optimised medical treatment reduced the severity of IBS symptoms, with a larger effect size in the diet groups. Dietary interventions might be considered as an initial treatment for patients with IBS. Research is needed to enable personalised treatment strategies.
Funding
The Healthcare Board Region Västra Götaland, the Swedish Research Council, the Swedish Research Council for Health, Working Life and Welfare, AFA Insurance, grants from the Swedish state, the Wilhelm and Martina Lundgren Science Foundation, Skandia, the Dietary Science Foundation, and the Nanna Swartz Foundation.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Access any 5 articles from the Lancet Family of journals
Subscribe:
Subscribe to The Lancet Gastroenterology & Hepatology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- 1.
Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study.Gastroenterology. 2021; 160: 99-114
- 2.
Bowel disorders.Gastroenterology. 2016; 150: 1393-1407
- 3.
Visceral hypersensitivity in irritable bowel syndrome.J Gastroenterol Hepatol. 2011; 26: 119-121
- 4.
Interaction between preprandial and postprandial rectal sensory and motor abnormalities in IBS.Gut. 2014; 63: 1441-1449
- 5.
Rome IV—functional GI disorders: disorders of gut-brain interaction.Gastroenterology. 2016; 150: 1257-1261
- 6.
Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life.Am J Gastroenterol. 2013; 108: 634-641
- 7.
Irritable bowel syndrome with food-related symptoms: future directions in the clinical management.United European Gastroenterol J. 2022; 10: 594-600
- 8.
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome.Gut. 2021; 70: 1214-1240
- 9.
Diet or medication in primary care patients with IBS: the DOMINO study—a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute.Gut. 2022; 71: 2226-2232
- 10.
Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance.BMJ. 2015; 350: h701
- 11.
The low FODMAP diet for treatment of irritable bowel syndrome and other gastrointestinal disorders.Gastroenterol Hepatol (N Y). 2013; 9: 450-452
- 12.
Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon.Aliment Pharmacol Ther. 2010; 31: 874-882
- 13.
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis.Gut. 2022; 71: 1117-1126
- 14.
Adult sucrase-isomaltase deficiency masquerading as IBS.Gut. 2022; 71: 1237-1238
- 15.
A very low-carbohydrate diet improves symptoms and quality of life in diarrhoea-predominant irritable bowel syndrome.Clin Gastroenterol Hepatol. 2009; 7: 706-708
- 16.
Assessment of a 4-week starch- and sucrose-reduced diet and its effects on gastrointestinal symptoms and inflammatory parameters among patients with irritable bowel syndrome.Nutrients. 2021; 13: 416
- 17.
The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress.Aliment Pharmacol Ther. 1997; 11: 395-402
- 18.
The role of carbohydrates in irritable bowel syndrome: protocol for a randomized controlled trial comparing three different treatment options.JMIR Res Protoc. 2022; 11e31413
- 19.
Nordic nutrition recommendations 2012: integrating nutrition and physical activity.Narayana Press, Copenhagen2014
- 20.
Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial.Gastroenterology. 2015; 149: 1399-1407
- 21.
A randomized controlled trial comparing the low FODMAP diet versus modified NICE guidelines in US adults with IBS-D.Am J Gastroenterol. 2016; 111: 1824-1832
- 22.
Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome.Aliment Pharmacol Ther. 2010; 32: 144-158
- 23.
ACG Clinical Guideline: management of irritable bowel syndrome.Am J Gastroenterol. 2021; 116: 17-44
- 24.
A dietary intervention with reduction of starch and sucrose leads to reduced gastrointestinal and extra-intestinal symptoms in IBS patients.Nutrients. 2019; 111662
- 25.
The effect of starch- and sucrose-reduced diet accompanied by nutritional and culinary recommendations on the symptoms of irritable bowel syndrome patients with diarrhoea.Therap Adv Gastroenterol. 2023; 16 (17562848231156682)
- 26.
The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS.Gut. 2017; 66: 1517-1527
- 27.
A high-fat diet temporarily accelerates gastrointestinal transit and reduces satiety in men.Int J Food Sci Nutr. 2011; 62: 857-864
- 28.
Sugar fructose triggers gut dysbiosis and metabolic inflammation with cardiac arrhythmogenesis.Biomedicines. 2021; 9: 728
- 29.
Changes in serum and urinary metabolomic profile after a dietary intervention in patients with irritable bowel syndrome.PLoS One. 2021; 16e0257331
- 30.
Weznaver CNS, Simrén M, Törnblom H, Störsrud S, Jakobsson S. Patients' experiences of dietary changes during a structured dietary intervention for irritable bowel syndrome. UEG Week 2022 Poster Presentations; Oct 8–11, 2022.
Article info
Publication history
Published: April 18, 2024
Identification
Copyright
© 2024 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Articles
- Managing irritable bowel syndrome: balancing diet and pharmacotherapy
-
The pathophysiology of irritable bowel syndrome (IBS) includes multiple peripheral and central factors. Restrictive dietary interventions and pharmacotherapy are frequently used to treat individuals with IBS. However, comparative appraisal of their efficacies is missing. Although a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) has been shown to be efficacious in IBS, there is a notable shortage of studies on FODMAP reintroduction and personalisation.
- Full-Text
-
- Correction to Lancet Gastroenterol Hepatol 2024; 9: 507–20
-
Nybacka S, Törnblom H, Josefsson A, et al. A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial. Lancet Gastroenterol Hepatol 2024; 9: 507–20—In the title of this Article, the spelling of CARIBS was incorrect. This correction has been made to the online version as of May 8, 2024, and the printed version is correct.
- Full-Text
-